top of page


CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe
The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation.

nuaxia
1 day ago2 min read


European Commission authorises Nezglyal for cerebral adrenoleukodystrophy
The EU authorisation introduces a pharmacological treatment for eligible boys with cerebral adrenoleukodystrophy under exceptional circumstances.

nuaxia
Sep 281 min read
bottom of page